|Bid||30.87 x 1000|
|Ask||30.95 x 2200|
|Day's Range||29.81 - 30.98|
|52 Week Range||14.81 - 50.20|
|Beta (3Y Monthly)||2.15|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||36.17|
Portola Pharmaceuticals Inc NASDAQ/NGS:PTLAView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is extremely high for PTLA with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting PTLA. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding PTLA totaled $3.35 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Portola Pharmaceuticals, Inc.® (PTLA) today announced full results from ANNEXA-4, the Company’s Phase 3b/4 trial of its Factor Xa inhibitor antidote Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo] in patients experiencing acute major bleeding while taking a Factor Xa inhibitor. Anti-Factor Xa activity is a measure of the anticoagulant activity of apixaban, rivaroxaban, edoxaban and enoxaparin, the anticoagulants studied in ANNEXA-4.
Want to participate in a short research study? Help shape the future of investing tools and receive a $60 prize! I am going to run you through how I calculated Read More...
Portola Pharmaceuticals, Inc.® (PTLA) today announced that it will host a webcast and conference call to discuss the Company’s financial results for the quarter and full year ended December 31, 2018, and provide a general business overview on Friday, March 1, 2019, at 8:30 a.m. ET (5:30 a.m. PT). Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s two FDA-approved medicines are Bevyxxa® (betrixaban), the first and only oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness, and Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote for the Factor Xa inhibitors rivaroxaban and apixaban.
Portola Pharmaceuticals, Inc.® (PTLA) today announced that full results from the Company’s ANNEXA-4 study of Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo] have been accepted as a late-breaking oral presentation during the International Stroke Conference (ISC) 2019. Andexxa received both U.S. Orphan Drug and U.S. Food and Drug Administration (FDA) Breakthrough Therapy designations, and was approved on May 3, 2018 under the FDA's Accelerated Approval pathway.
Portola Pharmaceuticals, Inc.® (PTLA) today announced the appointment of Sheldon Koenig as executive vice president and chief commercial officer, effective immediately. Mr. Koenig brings to his new role more than three decades of global commercial leadership and operations experience.
Why Portola Pharmaceuticals Rose 8.09% on January 4 ## Stock performance On January 4, Portola Pharmaceuticals stock closed at $19.38, an 8.09% increase from its prior close of $17.93 on January 3. On December 31, 2018, Portola Pharmaceuticals stock price grew ~14.22% to reach $19.52 from its prior close of $17.09 on December 28. The stock price on January 4 was ~65% below its 52-week high of $55.48 on January 29, 2018. The company hit its 52-week low of $14.81 on December 24, 2018. ## Recent developments On December 2018, the US FDA (Food and Drug Administration) approved Portola Pharmaceuticals’ PAS (prior approval supplement) for large-scale, second-generation Andexxa. The approval enables a wide commercial launch of Andexxa in the US market. In May 2018, the FDA approved Andexxa under the accelerated approval pathway. The FDA also granted Andexxa an orphan drug designation and a breakthrough therapy designation. The approval is expected to boost the commercial launch of Andexxa in the US market, which in turn could significantly boost the revenue growth of Portola in 2019. ## Financials in a nutshell In the first nine months of 2018, Portola Pharmaceuticals’ net revenues grew ~95% YoY to reach $24.8 million from $12.7 million. Wall Street analysts estimate that Portola Pharmaceuticals will generate net revenues of $35.70 million, which represents ~58.35% YoY growth. The revenue growth of Portola Pharmaceuticals (PTLA) could boost the SPDR S&P Biotech ETF (XBI). The company makes up about ~1.31% of XBI’s total portfolio holdings. In the first nine months of 2018, Portola reported net income and EPS of -$261.7 million and -$3.97, respectively, compared to -$194.3 million and -$3.38 in the same period the prior year. Wall Street analysts estimate that Portola Pharmaceuticals will report net income and EPS of -$333.57 million and -$5.03, respectively, in fiscal 2018. ## Analysts’ recommendations Of the seven analysts tracking Portola Pharmaceuticals in January 2019, three of them recommended a “strong buy,” two analysts recommended a “buy” rating, and two analysts recommended a “hold” rating. On January 7, 2019, the company had a consensus 12-month target price of $35.83, which represents a ~84.88% return on investment over the next 12 months.
Portola Pharmaceuticals (PTLA) announces FDA approval for large-scale Generation II manufacturing process for Andexxa to support commercial launch expected this month.
Portola Pharmaceuticals Inc. shares jumped Monday after the company announced that the Food and Drug Administration had given an approval that should lead to the launch of its Andexxa drug. Portola's stock was halted ahead of the news, then jumped about 13% after trading resumed at 3:40 p.m. Eastern time. Portola said the FDA had approved a "prior approval supplement" for Andexxa, "allowing for broad commercial launch in the United States," according to the announcement. Andexxa is a drug used to counteract anticoagulent drugs that are used to treat conditions such as a stroke in cases of life-threatening or uncontrolled bleeding. "It is clear from the response to the Andexxa Early Supply Program that there is significant need for a specific reversal agent that can address life-threatening bleeding" that comes as a result of using the other life-saving drugs, Portola Chief Executive Scott Garland said in Monday's announcement. The drug was originally approved by the FDA in May. Portola shares had declined about 60% so far this year, as the S&P 500 index has declined 7%.
Portola Pharmaceuticals, Inc.® (PTLA) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Prior Approval Supplement (PAS) for its large-scale, second generation Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], allowing for broad commercial launch in the United States. Andexxa received both U.S. Orphan Drug and FDA Breakthrough Therapy designations and was initially approved on May 3, 2018 under the FDA's Accelerated Approval pathway.
Portola Pharmaceuticals, Inc.'s (NASDAQ:PTLA): Portola Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics that could advance the fields of thrombosis and other Read More...
The company's struggling to make the shift to commercial-stage biotech, and recent news raises questions on when this will change.
The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund positions. Our extensive review […]
Today, Portola Pharmaceuticals is trading at $19.32, which is a ~7.52% decline from yesterday’s close of $20.89 on December 10. That day, the stock price closed at $20.89, which is a ~63% fall from its 52-week high of $56.70 on December 21, 2017. The stock price fell from $48.68 at the close of the market on December 29, 2017, to $20.89 on December 10, 2018, reflecting a ~57% YTD (year-to-date) fall. Portola Pharmaceuticals hit a 52-week low of $18.18 on November 7.
Shares of Portola Pharmaceuticals Inc. slid about 6% Tuesday, after the company said a European committee has extended the review period for approval of a treatment for bleeding that has already been approved in the U.S. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has provided the company with a list of questions related to data submitted for its Ondexxya product, which is being reviewed for the reversal of the anticoagulant effects of the Factor Xa inhibitors apixaban and rivaroxaban in patients experiencing uncontrolled or life-threatening bleeding. The company has a deadline of Jan. 29 for responses, followed by a 30-day assessment period for the committee. "We will work diligently to address the Committee's questions as they review and further consider the data package supporting the MAA," Portola Chief Executive Scott Garland said in a statement. An opinion is now expected by Feb. 28 of 2019. The product was approved by the U.S. Food and Drug Administration in May and is being sold under the name Andexxa. Portola shares have fallen 60% in 2018, while the S&P 500 has fallen 0.6%.
Portola Pharmaceuticals, Inc.® (PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has extended the review period for the Company’s marketing authorization application (MAA) for Ondexxya™ (andexanet alfa), and cancelled the Oral Explanation scheduled for Wednesday, December 12, 2018. The CHMP informed Portola yesterday that it will provide a list of outstanding questions related to the data package the Company submitted for Ondexxya last quarter, which will require additional responses from the Company.
NEW YORK, Dec. 04, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
– Early Signs of Durable Response Across Patients with Relapsed/Refractory PTCL – – 50 Percent Complete Response Rate Observed in Patients with AITL – – Rapid and Significant.
On November 8, after Portola Pharmaceuticals released its third-quarter financial results, the stock price rose 21.41%. On November 8, Portola Pharmaceuticals stock price closed at $23.14, which was ~21.41% growth from its previous close of $19.06. On November 7, Portola Pharmaceuticals stock price closed at $19.06, which was ~2.80% growth from its previous close of $18.54. On November 7, the company hit its 52-week low of $18.18.
This biotech is rethinking its priorities as it tries to successfully make the leap to a commercial-stage company.